InNexus Biotechnology Inc. (TSX:IXS.V), a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announces that its shareholders have approved all resolutions at the Annual Shareholders Meeting of May 24, 2011. The following resolutions were approved:
